查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1620760

一次电池市场：按产地、电池类型和最终用户划分 - 2025-2030 年全球预测

Primary Cells Market by Origin (Animal Primary Cells, Human Primary Cells), Cell Type (Dermatocytes, Gastrointestinal Cells, Heart Cells), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年一次电池市值为14.3亿美元，预计到2024年将达到16亿美元，复合年增长率为12.10%，预计到2030年将达到31.8亿美元。

由于一次电池在电池生理学研究和生命科学药物开发中的重要作用，一次电池市场正在显着扩大。一次电池直接从活体组织中收集并保留其原始功能和基因，因此它们对于比电池库存更严肃的生物研究至关重要。需求范围从模拟体内条件到生物医学研究、药物发现和组织工程的相关性。应用范围广泛，包括癌症研究、心血管研究和神经科学，最终用户主要是研究机构、製药公司和生物技术公司。生物技术的进步、对个人化医疗的日益关注以及政府对电池研究的资助增加是影响该市场成长的关键因素。快速成长的再生医学领域带来了庞大的商机，一次电池成为开发新型治疗候选药物的关键要素。然而，分离和维护电池的高昂成本，以及对动物和人类电池来源的道德担忧，为市场成长带来了挑战。 3D 电池培养和 CRISPR 基因编辑等创新有可能带来突破，并为研究人员提供更具成本效益和更有效率的工具。对公司来说，投资这些领域以保持竞争力将是有利的。多中心研究合作以及与学术机构的伙伴关係可以透过汇集资源和知识来帮助克服一些限制，从而扩大目前的应用并加速发展。创新的关键部分之一是创建标准化且价格实惠的原电池菌株，可减少变异性并提高研究结果的可重复性。市场是充满活力和竞争的，公司必须不断适应新的科学发现和技术进步，以保持该领域的成长和相关性。

主要市场统计
基准年[2023] 14.3亿美元
预计年份 [2024] 16亿美元
预测年份 [2030] 31.8亿美元
复合年增长率（%） 12.10%

市场动态：揭示一次电池

供需的动态互动正在改变一次电池市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 扩大药物筛检和电池检测的接受度
    • 与其他现有方法相比，第一代体细胞的优势
    • 对单株抗体和个人化医疗的兴趣日益浓厚
  • 市场限制因素
    • 常见的电池文化问题，例如污染
  • 市场机会
    • 生物技术和生物製药产业的扩张
    • 一次电池生物医学研究进展
  • 市场问题
    • 电池生物学研究领域的伦理问题

波特五力：驾驭一次电池市场的策略工具

波特五力框架是了解一次电池市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解外部对一次电池市场的影响

外部宏观环境因素对一次电池市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解一次电池市场竞争状况

对一次电池市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵：一次电池市场厂商绩效评估

FPNV定位矩阵是评估一次电池市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製一次电池市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，一次电池市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开发：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、未开发地区、主要产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 药物筛检和电池检测的普及
      • 与现有方法相比，人类原代细胞的优势
      • 单株抗体和个人化医疗日益受到关注
    • 抑制因素
      • 常见的电池文化问题，例如污染
    • 机会
      • 生物技术和生物製药产业的扩张
      • 使用一次电池的生物医学研究进展
    • 任务
      • 电池生物学研究领域的伦理问题
  • 市场区隔分析
    • 起源：人们越来越倾向于使用人类一次电池来准确地表示人类电池反应
    • 电池类型：在药物开发和毒理学测试中越来越多地采用皮肤电池
    • 最终用户：生命科学公司使用一次电池的数量激增，以确保实验过程中获得准确的结果
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章一次电池市场：依来源分类

  • 介绍
  • 动物
  • 人类

第七章一次电池市场：依电池类型

  • 介绍
  • 皮肤电池
  • 胃肠电池
  • 心臟电池
  • 造血电池
  • 肝臟电池
    • 冻存肝电池
    • 新鲜肝臟电池
  • 肺电池
  • 肌肉骨骼电池
  • 肾臟电池

第八章一次电池市场：依最终用户分类

  • 介绍
  • 生命科学公司
  • 研究所

第九章 北美、南美一次电池市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太一次电池市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东、非洲一次电池市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • CN Bio 和 LifeNet Health LifeSciences 合作为微生理学系统提供检验的第一代体细胞
    • AnaBios 收购 Cell Systems 以扩大用于药物发现的人体电池产品组合
    • Human Cell Design 推出 Endoc-BH5，这是一种先进的人类 β 细胞模型，可为 1 型和 2 型糖尿病研究带来新发现
  • 战略分析和建议

公司名单

  • Biopredic International
  • Corning Incorporated
  • Danaher Corporation
  • FUJIFILM Irvine Scientific, Inc.
  • Lonza AG
  • PromoCell GmbH
  • Reachbio LLC
  • Sciencell Research Laboratories, Inc.
  • Sekisui Xenotech, LLC
  • Stem Cell Technologies, Inc.
  • StemExpress, LLC
  • The Bio Convergence Company
  • The Merck Group
  • Thermo Fisher Scientific, Inc.
  • Zenbio, Inc.
Product Code: MRR-4F4C36263622

The Primary Cells Market was valued at USD 1.43 billion in 2023, expected to reach USD 1.60 billion in 2024, and is projected to grow at a CAGR of 12.10%, to USD 3.18 billion by 2030.

The market for primary cells is expanding significantly, driven by their essential role in life sciences for studying cellular physiology and drug development. Primary cells are directly obtained from living tissues, retaining native functions and genetics, which makes them indispensable for more authentic biological research compared to cell lines. Their necessity spans across biomedical research, drug discovery, and tissue engineering due to their relevance in mimicking in vivo conditions. Applications are extensive including cancer research, cardiovascular studies, and neuroscience, with end-users predominantly comprising research institutes, pharmaceutical companies, and biotechnology firms. Key growth influencers in the primary cells market include advancements in biotechnology, a heightened focus on personalized medicine, and increasing government funding for cell-based research. The burgeoning field of regenerative medicine presents substantial opportunities, with primary cells serving as a crucial component for developing novel therapeutic candidates. However, market growth is challenged by the high costs of cell isolation and maintenance and the ethical concerns regarding animal and human-derived cell sources. Technological innovations such as 3D cell cultures and CRISPR gene editing could provide breakthroughs, offering more cost-effective and efficient tools for researchers. It would be beneficial for companies to invest in these areas to stay competitive. Multi-center collaborations and partnerships with academic institutions can help overcome some limitations by pooling resources and knowledge, thus expanding the current applications and expediting development. One of the key areas for innovation is in creating standardized and affordable primary cell lines that can reduce variability and enhance reproducibility of research outcomes. The market is dynamic and competitive, requiring businesses to stay adaptive to new scientific discoveries and technological advancements to maintain growth and relevance in the field.

KEY MARKET STATISTICS
Base Year [2023] USD 1.43 billion
Estimated Year [2024] USD 1.60 billion
Forecast Year [2030] USD 3.18 billion
CAGR (%) 12.10%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Primary Cells Market

The Primary Cells Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing acceptance in drug screening and cell based assays
    • Advantages of primary human cells over other existing methods
    • Growing focus on monoclonal antibodies and personalized medicine
  • Market Restraints
    • Common cell culture problems such as contamination
  • Market Opportunities
    • Expanding biotechnology and biopharmaceutical industries
    • Advancements in biomedical research using primary cells
  • Market Challenges
    • Ethical issues in cell biology research field

Porter's Five Forces: A Strategic Tool for Navigating the Primary Cells Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Primary Cells Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Primary Cells Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Primary Cells Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Primary Cells Market

A detailed market share analysis in the Primary Cells Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Primary Cells Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Primary Cells Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Primary Cells Market

A strategic analysis of the Primary Cells Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Primary Cells Market, highlighting leading vendors and their innovative profiles. These include Biopredic International, Corning Incorporated, Danaher Corporation, FUJIFILM Irvine Scientific, Inc., Lonza AG, PromoCell GmbH, Reachbio LLC, Sciencell Research Laboratories, Inc., Sekisui Xenotech, LLC, Stem Cell Technologies, Inc., StemExpress, LLC, The Bio Convergence Company, The Merck Group, Thermo Fisher Scientific, Inc., and Zenbio, Inc..

Market Segmentation & Coverage

This research report categorizes the Primary Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Origin, market is studied across Animal Primary Cells and Human Primary Cells.
  • Based on Cell Type, market is studied across Dermatocytes, Gastrointestinal Cells, Heart Cells, Hematopoietic Cells, Hepatocytes, Lung Cells, Musculoskeletal Cells, and Renal Cells. The Hepatocytes is further studied across Cryopreserved Hepatocytes and Fresh Hepatocytes.
  • Based on End-User, market is studied across Life Science Companies and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing acceptance in drug screening and cell based assays
      • 5.1.1.2. Advantages of primary human cells over other existing methods
      • 5.1.1.3. Growing focus on monoclonal antibodies and personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Common cell culture problems such as contamination
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding biotechnology and biopharmaceutical industries
      • 5.1.3.2. Advancements in biomedical research using primary cells
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical issues in cell biology research field
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Origin: Increasing preference for human primary cells for accurate representations of human cellular responses
    • 5.2.2. Cell Type: Rising adoption of dermatocytes in drug development and toxicity testing
    • 5.2.3. End-User: Proliferating use of primary cells in life science companies to ensure accurate results during experimentation
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Primary Cells Market, by Origin

  • 6.1. Introduction
  • 6.2. Animal Primary Cells
  • 6.3. Human Primary Cells

7. Primary Cells Market, by Cell Type

  • 7.1. Introduction
  • 7.2. Dermatocytes
  • 7.3. Gastrointestinal Cells
  • 7.4. Heart Cells
  • 7.5. Hematopoietic Cells
  • 7.6. Hepatocytes
    • 7.6.1. Cryopreserved Hepatocytes
    • 7.6.2. Fresh Hepatocytes
  • 7.7. Lung Cells
  • 7.8. Musculoskeletal Cells
  • 7.9. Renal Cells

8. Primary Cells Market, by End-User

  • 8.1. Introduction
  • 8.2. Life Science Companies
  • 8.3. Research Institutes

9. Americas Primary Cells Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Primary Cells Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Primary Cells Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. CN Bio and LifeNet Health LifeSciences Partner to Supply Validated Primary Human Cells for Microphysiological Systems
    • 12.3.2. AnaBios Acquires Cell Systems, Expands Human Cell Portfolio for Drug Discovery
    • 12.3.3. Human Cell Design Launches Endoc-BH5, an Advanced Human Beta Cell Model enabling New Discoveries in Type 1 and 2 Diabetes Research
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Biopredic International
  • 2. Corning Incorporated
  • 3. Danaher Corporation
  • 4. FUJIFILM Irvine Scientific, Inc.
  • 5. Lonza AG
  • 6. PromoCell GmbH
  • 7. Reachbio LLC
  • 8. Sciencell Research Laboratories, Inc.
  • 9. Sekisui Xenotech, LLC
  • 10. Stem Cell Technologies, Inc.
  • 11. StemExpress, LLC
  • 12. The Bio Convergence Company
  • 13. The Merck Group
  • 14. Thermo Fisher Scientific, Inc.
  • 15. Zenbio, Inc.

LIST OF FIGURES

  • FIGURE 1. PRIMARY CELLS MARKET RESEARCH PROCESS
  • FIGURE 2. PRIMARY CELLS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PRIMARY CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PRIMARY CELLS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PRIMARY CELLS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PRIMARY CELLS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PRIMARY CELLS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PRIMARY CELLS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PRIMARY CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PRIMARY CELLS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PRIMARY CELLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PRIMARY CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PRIMARY CELLS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PRIMARY CELLS MARKET DYNAMICS
  • TABLE 7. GLOBAL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PRIMARY CELLS MARKET SIZE, BY ANIMAL PRIMARY CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PRIMARY CELLS MARKET SIZE, BY HUMAN PRIMARY CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PRIMARY CELLS MARKET SIZE, BY DERMATOCYTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PRIMARY CELLS MARKET SIZE, BY GASTROINTESTINAL CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEART CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEMATOPOIETIC CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PRIMARY CELLS MARKET SIZE, BY CRYOPRESERVED HEPATOCYTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PRIMARY CELLS MARKET SIZE, BY FRESH HEPATOCYTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PRIMARY CELLS MARKET SIZE, BY LUNG CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PRIMARY CELLS MARKET SIZE, BY MUSCULOSKELETAL CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PRIMARY CELLS MARKET SIZE, BY RENAL CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PRIMARY CELLS MARKET SIZE, BY LIFE SCIENCE COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PRIMARY CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES PRIMARY CELLS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. PRIMARY CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. PRIMARY CELLS MARKET, FPNV POSITIONING MATRIX, 2023